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Estrogen receptor-mediated enhancement of
venous relaxation in female rat: Implications in
sex-related differences in varicose veins
Joseph D. Raffetto, MDa,b,c Xiaoying Qiao, MD, PhD,a Katie G. Beauregard, BS,a and
Raouf A. Khalil, MD, PhD,a,b Boston and West Roxbury, Mass
Background: A greater incidence of varicose veins has been reported in premenopausal women than in men. We
hypothesized that the sex differences in venous function reflect reduced constriction and enhanced venous dilation in
women due to direct venous relaxation effects of estrogen on specific estrogen receptors (ER).
Methods: Circular segments of inferior vena cava (IVC) from male and female Sprague-Dawley rats were suspended
between two wires, and isometric contraction (in mg/mg tissue) to phenylephrine, angiotensin II (AngII), and 96 mM
KCl was measured. To investigate sex differences in venous smooth muscle, Ca2 release from the intracellular stores, and
Ca2 entry from the extracellular space, the transient phenylephrine contraction in 0 Ca2 Krebs was measured.
Extracellular CaCl2 (0.1, 0.3, 0.6, 1, 2.5 mM) was added, and the [Ca2]e-dependent contraction was measured. To
investigate sex differences in venous endothelial function, acetylcholine-induced relaxation was measured. To test the role
of specific ERs, the amount of venous tissue ERs was measured usingWestern blots, and the venous relaxation in response
to 17-estradiol (E2, activator of most ERs), 4,4,=4==-(4-propyl-[1H]-pyrazole-1,3,5-triyl)-tris-phenol (PPT; ER
agonist), 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN; ER agonist), and ICI 182,780 (ER/ER antagonist, and G
protein-coupled receptor 30 [GPR30] agonist) was measured in IVC segments nontreated or treated with the nitric oxide
synthase (NOS) inhibitor N-nitro-L-arginine methyl ester (L-NAME).
Results:Phenylephrine caused concentration-dependent contraction thatwas less in female (max 104.216.2) thanmale IVC
(172.4  20.4). AngII (106)-induced contraction was also less in female (81.0  11.1) than male IVC (122.5  15.0).
Phenylephrine contraction in 0Ca2Krebswas insignificantly less in female (4.81.8) thanmale IVC (7.21.7), suggesting
little difference in the intracellular Ca2 release mechanism. In contrast, the [Ca2]e-dependent contraction was significantly
reduced in female thanmale IVC.Also, contraction tomembrane depolarization by 96mMKCl,which stimulatesCa2 influx,
was less in female (129.7  16.7) than male IVC (319.7  30.4), supporting sex differences in Ca2 entry. Acetylcholine
relaxation was greater in female (max 80.6%  4.1%) than male IVC (max 48.0%  6.1%), suggesting sex differences in the
endothelium-dependent relaxation pathway.Western blots revealed greater amounts of ER, ER, andGPR30 in female than
male IVC. ER agonists caused concentration-dependent relaxation of phenylephrine contraction in female IVC. E2-induced
relaxation (max76.5%3.4%)wasmore thanDPN(74.8%9.1%), PPT (71.4%12.5%), and ICI182,780 (67.4%7.8%),
and was similar in L-NAME-treated and nontreated IVC.
Conclusion: The reduced -adrenergic, AngII, depolarization-induced, and [Ca2]e-dependent venous contraction in female
rats is consistent with sex differences in the Ca2 entry mechanisms, possibly due to enhanced endothelium-dependent
vasodilation and increased ER expression/activity in female rats. E2/ER-mediated venous relaxation in female rats is not
prevented by NOS blockade, suggesting activation of an NO-independent relaxation pathway. The decreased venous
contraction and enhanced E2/ER-mediated venous relaxation would lead to more distensible veins in female rats. (J Vasc
Surg 2010;51:972-81.)
Clinical Relevance: Studies have demonstrated an increase in the incidence of varicose veins in women compared with men,
suggesting potential role of endogenous sex hormones.However, little is known regarding the difference in function of venous
tissues of women and men and their vasoreactive responses to various agonists and to specific estrogenic compounds. The
present data in rat veins demonstrate a gender-related decrease in venous tissue contraction and an enhanced endothelium-
dependent venous relaxation pathway, possibly due to increased expression of venous tissue estrogen receptor-, estrogen
receptor-, and G protein-coupled receptor 30, and downstream activation of the nitric oxide-independent pathway. The
enhanced estrogen-mediated venous relaxation pathways may promote venous dilation and lead to more distensible veins in
female rats. Future studies in human veins should investigate the possibility of gender differences in estrogen receptor-
mediated venous relaxation pathways and thereby explain the higher prevalence of varicose veins in women.
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Volume 51, Number 4 Raffetto et al 973Varicose veins is a common disease of the lower extrem-
ity characterized by valve degeneration and vein wall dila-
tion and tortuousity.1 Several predisposing factors have
been implicated in varicose veins, including diabetes, obe-
sity, smoking, and age.2,3 Gender could also influence the
incidence of varicose veins. Sex differences in the prevalence
of varicose veins have been reported, with a greater inci-
dence in women compared with men.4,5
Prevalence estimates of varicose veins could be as low as
1% to 2% in men and women, but could reach 56% in men
and as high as 73% in women.2,3,6 Specifically, the inci-
dence rate of varicose veins in the Framingham Heart Study
was greater in women (2.6%) than in men (1.9%).7 The San
Diego Population Study, a cross-sectional study of a mul-
tiethnic sample of 2211 men and women, demonstrated
varicose veins in 28% of adult women compared with 15%
of adult men.8
Gender differences could be related to hormonal influ-
ence as evidenced by the increased incidence of varicose
veins in women during pregnancy and with the use of oral
contraceptives containing estrogen (E2).2,9-12 However,
the venous mechanisms underlying the gender differences
and the role of sex hormones in the incidence of varicose
veins are unclear.
Sex differences in arterial function have been demon-
strated in the aorta, coronary, mesenteric, and renal arter-
ies.13-20 We have previously shown that aortic contraction
is reduced in female compared with male rats.16,17 Studies
from our laboratory and others have also suggested that the
sex differences in arterial vasoconstriction are likely due to
the high levels of E2 in females.16,17,21-23 E2 induces
long-term genomic effects involving up-regulation of en-
dothelium-dependent vascular relaxation pathways such as
nitric oxide (NO), prostacyclin (PGI2), and endothelium-
derived hyperpolarizing factor (EDHF).24,25 E2 also in-
duces down-regulation of the mechanisms of vascular smooth
muscle contraction, including Ca2 channels and protein
kinase C.17,26 In addition to its long-term effects, E2
promotes rapid nongenomic effects involving activation of
endothelium-derived vasodilators and inhibition of the Ca2-
dependent mechanisms of arterial contraction.23-25,27,28
Estrogen receptors (ERs) have been characterized in
the female reproductive tract, mammary glands, and other
tissues.29 ERs have also been identified in blood ves-
sels.30-32 Two major ERs, ER and ER, have been sug-
gested to mediate many of the genomic effects of
E2.29,31,32 Surface membrane ERs have also been impli-
cated in the rapid vasodilator effects of E2.27 A new trans-
membrane G protein-coupled receptor, GPR30, has also
been shown to bind E2 and to mediate some of its rapid
effects.33-36
Although numerous studies have examined the sex
difference and the effects of E2 on arterial function, little is
known regarding the sex differences and the effects of E2
on venous function. Also, although ER, ER, and GPR30
have been characterized in numerous arterial preparations
from human and experimental animals,15,30-32,35 theamount and functional significance of ERs in venous tissues
are less clear.
Recent experiments from our laboratory have demon-
strated a reduction in [Ca2]i signaling and Ca
2-dependent
contraction in female rat inferior vena cava (IVC) segments
loaded with the Ca2 indicator fura-2.37 The present study
was designed to test the hypothesis that the sex differences
in venous function reflect reduced venous constriction as
well as enhanced venous dilation in female rats compared
with male rats, partly due to direct effects of E2 on specific
ERs in venous tissues and downstream activation of ER-
mediated venous relaxation pathways.
METHODS
All procedures in this study followed the National
Institutes of Health guide for the Care of Laboratory
Animal Welfare Act and the guidelines of the Animal Care
and Use Committee at Harvard Medical School.
Animals and tissues. Male (n 6) and female (n 6)
Sprague-Dawley rats (age, 12 weeks old; weight, 250-300
g; Charles River Lab, Wilmington, Mass) were maintained
on ad libitum standard rat chow and tap water in a 12 h
light/12 h dark cycle.
Rats were euthanized by inhalation of CO2. The IVC
was rapidly excised, placed in oxygenated Krebs solution,
and carefully dissected and cleaned of connective tissue
under microscopic visualization. The IVC was portioned
into 3-mm rings in preparation for isometric contraction
experiments. Four 3-mm-long segments were obtained
from each rat IVC. All vein segments were obtained from
the IVC below the renal veins. Extreme care was taken
throughout the tissue isolation and dissection procedure to
minimize injury to the endothelium and the vein wall.
In all experiments, the IVC was harvested freshly and
dissected immediately in normal Krebs solution. The time
between harvesting the IVC, removing the fat and connec-
tive tissue, and sectioning it into 3-mm rings was approxi-
mately 45 minutes. One vein segment from each rat was
used to perform one experiment and obtain one data point.
Data from one to four vein segments from different rats
were used to calculate the average data for each arm of the
study.
Isometric contraction. Circular segments of IVC
were suspended between two stainless-steel hooks, one
hook was fixed at the bottom of a tissue bath, and the other
hook was connected to a Grass force displacement trans-
ducer (FT03, Astro-Med Inc, West Warwick, RI). Vein
segments were stretched under 0.5 g of resting tension and
allowed to equilibrate for 45 minutes in a tissue bath filled
with 50 mL Krebs solution continuously bubbled with 95%
O2 and 5% CO2 at 37°C. We have previously constructed
the relationship between basal tension and the contraction
to 96 mM KCl in rat IVC, and demonstrated that 0.5 g
basal tension produced maximal KCl contraction. Further
increases in basal tension did not cause any significant
increases in IVC contraction in response to KCl.38 The
changes in isometric contraction/relaxation were recorded
on a Grass polygraph (Model 7D, Astro-Med Inc).38,39
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was first elicited. Once the KCl maximum contraction was
reached and a plateau achieved (within 10 to 15 minutes)
the tissue was washed three times in Krebs, 10 minutes
each. The control contraction to 96 mM KCl was repeated
twice before further experimentation.
IVC segments were then stimulated with increasing
concentrations (109 to 105 M) of phenylephrine (PHE),
and the contractile response was measured. To correct for
any undetectable differences in the vein segment size, all
contraction measurements were normalized for the weight
of the vein segments and presented as mg/mg tissue
weight. The contractile response at each PHE concentra-
tion was also presented as the percentage of the maximum
PHE contraction. The individual PHE concentration-
response curves were analyzed using a nonlinear regres-
sion curve (best-fit sigmoidal dose-response curve) using
SigmaPlot software (Systat Software, Inc, San Jose, CA).
The effective concentration that produced half the maximal
contraction (ED50) was presented as pED50 (–log M). In
other experiments, the tissues were treated with angioten-
sin II (AngII, 106 M), and the maximal peak contraction
was measured.
To investigate sex differences in Ca2 release from the
intracellular stores, IVC segments were incubated in Ca2-
free (2 mM ethyleneglycotetraacetic acid [EGTA]) Krebs
for 5 minutes and then in nominally 0 Ca2 Krebs for 5
minutes. The IVC segments were then stimulated with
PHE (105 M), and the peak transient contraction was
measured. To investigate sex differences in Ca2 influx,
increasing extracellular CaCl2 concentrations (0.1, 0.3,
0.6, 1, 2.5 mM) were added and the [Ca2]e-contraction
relationship was constructed.
To investigate sex differences in venous endothelial
function, IVC segments precontracted with PHE (105
M) were treated with increasing concentrations (109 to
105 M) of acetylcholine (Ach), and the percentage of ve-
nous relaxation was measured. To test the role of ERs, female
IVC segments precontracted with PHE (105 M) were
treated with increasing concentrations (1012 to 105 M) of
17-estradiol (E2, activator of most ERs), 4,4,=4==-(4-propyl-
[1H]-pyrazole-1,3,5-triyl)-tris-phenol (PPT, selective ER
agonist),40,41 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN,
selective ER agonist),42 and ICI 182,780 (fulvestrant, a
known ER antagonist that also possesses agonistic activity
at GPR30),43,44 and the percentage of venous relaxation
was measured. To test the role of ER-mediated endothelium-
dependent NO, experiments were repeated in IVC seg-
ments treated with the NO synthase (NOS) inhibitor
N-nitro-L-arginine methyl ester (L-NAME, 3 104M).
Western blot analysis. The venous tissue homoge-
nate was subjected to electrophoresis on 8% sodium dode-
cyl sulfate polyacrylamide gel and then transferred electro-
phoretically to nitrocellulose membrane. The membrane
was incubated in 5% dried nonfat milk for 1 hour and then
treated with polyclonal antibody to ER, (1:100), ER
(1:1000), and GPR30 (1:100; Affinity Bioreagents,
Golden, Colo) for 24 hours. -Actin was used as an internalcontrol and detected by a monoclonal antiactin antibody
(1:500000, Sigma, St. Louis, Mo).
The nitrocellulose membranes were washed five times
for 15 minutes each in Tris-buffered saline–Tween then
incubated in horseradish peroxidase-conjugated secondary
antibody (1:1000) for 1.5 hours. The blots were visualized
with enhanced chemiluminescence (ECL) Western Blot-
ting Detection Reagent (GE Healthcare Bio-Sciences
Corp, Piscataway, NJ), and the reactive bands were ana-
lyzed quantitatively by optical densitometry. The densi-
tometry values represented the pixel intensity and were
normalized to -actin to correct for loading.38
Solutions, drugs, and chemicals. Normal Krebs so-
lution contained (in mM) NaCl, 120; KCl, 5.9; NaHCO3,
25; NaH2PO4, 1.2; dextrose, 11.5 (Fisher Scientific, Fair
Lawn, NJ), CaCl2, 2.5 (BDH Laboratory Supplies Poole,
England), and MgCl2, 1.2 (Sigma). Krebs solution was bub-
bled with 95% O2 and 5% CO2 for 30 minutes at an adjusted
pH 7.4. For nominally 0 Ca2Krebs, CaCl2 was omitted. For
Ca2-free Krebs, CaCl2 was omitted and 2 mM EGTA
(Sigma) was added. KCl (96 mM) was prepared as normal
Krebs but with equimolar substitution of NaCl with KCl.
Stock solutions of PHE (101 M), AngII, (102 M), Ach
(101 M), and L-NAME (101M, Sigma) were prepared in
deinoized water, 17-estradiol (E2, 102M, Sigma) in
ethanol, and PPT, DPN, and ICI 182,780 (101M, Toc-
ris, Ellisville, Mo) in dimethylsulfoxide. The final concen-
tration of ethanol or dimethylsulfoxide was 0.1%. All
other chemicals were of reagent grade or better.
Statistical analysis. Data were analyzed and presented
as means	 standard error of the mean and compared using
the t test for unpaired data. Differences were considered
statistically significant if P  .05.
RESULTS
PHE caused a concentration-dependent contraction in
rat IVC that reached a maximum at 105M. The maximum
PHE contraction (mg/mg tissue) was significantly reduced
(P .012) in females (104.2	 16.2) compared with males
(172.4 	 20.4; Fig 1). When the PHE response was
measured as percentage of maximum contraction and the
EC50 calculated, PHE was equally potent in female
(pEC50 5.35% 	 0.37%) compared with male IVC seg-
ments (pEC50 5.22% 	 0.37%; Fig 1).
AngII (106 M) caused a transient contraction in rat
IVC that returned to baseline in 5 to 10 minutes. The peak
AngII contraction was significantly less in female compared
with male IVC (Fig 2, A). Membrane depolarization by 96
mM KCl, which stimulates Ca2 influx, caused a significant
and rapid initial IVC contraction, followed by a maintained
steady-state contraction. Both the initial and steady-state
KCl contraction were reduced in female compared with
male IVC (Fig 2, B). In nominally 0 Ca2 Krebs, PHE
(105 M) caused a small transient contraction representing
the response to Ca2 release from the intracellular stores.
The PHE contraction in 0 Ca2 Krebs was insignificantly
less in female (4.8 	 1.8) than male IVC (7.2 	 1.7
mg/mg tissue; Fig 2, C). The gradual addition of extracel-
iffere
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traction that reached a maximum at 2.5 mM [Ca2]e (Fig
2, C). The [Ca2]e-dependent contraction was signifi-
cantly reduced in female compared with male IVC.
To test for sex differences in endothelium-dependent
relaxation, the response to Ach was compared in female and
male IVC. In IVC segments precontracted with PHE
(105 M), increasing concentrations of Ach (109 to
105 M) caused concentration-dependent relaxation that
reached a maximum at 105M. Ach-induced relaxation was
significantly greater in female compared with male IVC
(Fig 3).
Western blot analysis of IVC tissue homogenate re-
vealed immunoreactive bands corresponding to ER at 64
kDa, ER at 55 kDa, and GPR30 at 50 kDa. Optical
density analysis revealed that the amount of ER, ER, and
GPR30 was significantly greater in female compared with
male IVC (Fig 4).
To test the functionality of ERs in rat IVC, the effects
of ER agonists on PHE contraction was measured (Fig 5).
E2 (1012 to 105 M) caused concentration-dependent
relaxation of female IVC that reached a maximum at 105
M E2. PPT (ER agonist), DPN (ER agonist), and ICI
182,780 (ER/ER antagonist and GPR30 stimulant)
also caused relaxation of female IVC that reached a maxi-
mum at 105 M (Fig 6). The maximal IVC relaxation was
76.5 	 3.4 for E2, 74.8 	 9.1 for DPN, 71.4 	 12.5 for
PPT, and 67.4 	 7.8 for ICI 182,780. The venorelaxant
effects of E2, DPN, and ICI 182,780 were reversible, and
Fig 1. Effect of phenylephrine (PHE) on male and fem
(2.5 mM Ca2). After two control 96 mM KCl contracti
and (B) female rats were stimulated with the -adrenergic
recorded and presented as (C) mg/mg tissue or as (D
represents a threefold greater PHE concentration than th
of the mean for 16 to 20 vein segments. *Significantly dafter washing the IVC segments three times with Krebs, asignificant PHE contraction could still be elicited. In con-
trast, the venorelaxant effect of PPT was irreversible, and no
PHE contraction could be measured after repeated wash-
ing with Krebs.
To determine the potential role of NO as a post-ER
downstream venous relaxation mechanism, we examined
the effect of treatment of female rat IVC with the NOS
inhibitor L-NAME (3 104 M) for 15 minutes. E2, PPT,
DPN, and ICI 182,780 caused similar relaxation of PHE
contraction in L-NAME treated and nontreated IVC
(Fig 7).
DISCUSSION
The main findings of the present study are (1) -
adrenergic-, AngII-, depolarization-induced, and [Ca2]e-
dependent contraction are reduced in female compared
with male IVC, (2) Ach-induced relaxation is greater in
female compared with male IVC, (3) female IVC has more
ERs than male IVC, and (4) selective ER agonists cause
relaxation of female IVC that is not blocked by NOS
inhibitor.
Although the male rat IVC is a very thin and delicate
preparation, we have previously shown that it produces
significant and consistent contraction in response to PHE
and membrane depolarization by high KCl.38,39 Therefore,
the rat IVC was an appropriate preparation to study the
sex differences in venous tissue function between males
and females. The -adrenergic agonist PHE produced
concentration-dependent contraction that was signifi-
at inferior vena cava (IVC) incubated in normal Krebs
ollowed by washing in Krebs, IVC segments of (A) male
ist PHE (109 to 105 M). The contractile response was
centage of maximal contraction. The unlabeled arrow
eding arrow. Data represent the means	 standard error
nt (P  .05).ale r
ons, f
agon
) per
e preccantly reduced in female compared with male IVC, sug-
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of venous constriction. To test whether the sex differences in
PHE contraction represent differences in the -adrenergic
receptor affinity to PHE, we compared the PHE EC50 in
female and male IVC. The lack of difference in PHE EC50
Fig 2. Angiotensin II (AngII), potassium chloride (KCl) and
calcium (Ca2)-dependent contraction in male and female rat
inferior vena cava (IVC) segments. IVC segments from male
(shaded bars) and female rats (white bars)were incubated in normal
Krebs (2.5 mM Ca2). The tissues were stimulated with the
angiotensin type 1 receptor agonist AngII (106 M) and the (A)
peak contractile response was measured or (B) with 96 mM KCl
depolarizing solution and the initial maximal contractile response
and steady-state contraction were recorded. C, Other IVC seg-
ments were incubated in Ca2-free (2 mM ethyleneglycotetraace-
tic acid) Krebs for 5 minutes, then nominally 0 Ca2 Krebs for 5
minutes, then stimulated with phenylephrine (PHE; 105 M) and
the transient contraction was measured. Increasing concentrations
of extracellular CaCl2 (0.1, 0.3, 0.6, 1, 2.5 mM) were added, and
the contractile response at different [Ca2]e was recorded. Data
represent the means	 standard error of the mean for 8 to 20 vein
segments. *Significantly different (P  .05).suggests that the reduced PHE contraction in female IVC isnot due to a decrease in the -adrenergic receptor binding
or sensitivity to PHE.
To test whether the reduced venous contraction in
Fig 3. Acetylcholine (Ach)-induced relaxation is shown in male
and female rat inferior vena cava (IVC) segments. IVC segments
were stimulated with phenylephrine PHE (105 M), and the
steady-state contraction was recorded. Increasing concentrations
of Ach (109 to 105 M) were added, and the percentage relax-
ation of PHE contraction was compared in male and female IVC.
Data represent the means 	 standard error of the mean for 20 to
23 vein segments. *Significantly different (P  .05).
Fig 4. Expression of estrogen receptor (ER), ER, and G
protein-coupled receptor 30 (GPR30)is shown in male and female
rat inferior vena cava (IVC). Tissue homogenates of male and
female IVC were prepared for Western blot analysis and the
amount of ERs were measured using antibodies to ER (1:100),
ER (1:1000), and GPR30 (1:100). The intensity of the immuno-
reactive bands was analyzed using optical densitometry and normal-
ized to the housekeeping protein actin. Data represent the means 	
standard error of the mean for three experiments.*Significantly differ-
ent (P .05).female IVC is specific to -adrenergic receptor-mediated
al ba
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mediated vasoconstrictive response. AngII is known to
cause vasoconstriction by stimulating angiotensin type 1
receptor.45 The observation that AngII-induced venous
constriction was also reduced in female compared with
male IVC suggests that the sex differences in venous con-
traction are not receptor-specific and may involve reduction
in postreceptor signaling mechanism.
The reduced contractile response in female compared
with male veins is less likely due to difference in the vein
thickness because the contractile response was normalized
to the vein size. Future histologic analysis and morphome-
try should further measure the tunica media thickness and
smooth muscle density in female compared with male veins.
Vascular smooth muscle (VSM) contraction is trig-
gered by increases in [Ca2]i due to initial Ca
2 release
from the intracellular stores and maintained Ca2 entry
from the extracellular space.17,46 Agonist-induced VSM
contraction in Ca2-free Krebs has been used as a measure
of the intracellular Ca2 release mechanism.17 The rela-
tively small PHE contraction in 0 Ca2 Krebs suggests a
small role of the Ca2 release mechanism in IVC contrac-
tion. Although the PHE contraction in 0 Ca2 Krebs was
Fig 5. Representative traces of estrogen receptor (ER)-
shown. Segments of female rat IVC were stimulated
contraction was recorded. IVC segments were (A) nontre
105 M) of (B) 17-estradiol (E2, activator of most E
1,3,5-triyl)-tris-phenol (PPT), (D) the ER agonist 2
182,780, a ER/ER antagonist and G protein-couple
observed. The vertical bars show 0.5 g, and the horizontless in female compared with male IVC, the difference wasnot statistically significant, suggesting little gender differ-
ences in the intracellular Ca2 release mechanism.
To test for sex differences in the venous Ca2 entry
mechanisms, we measured the PHE-induced IVC contrac-
tion at increasing [Ca2]e. The observation that the PHE-
induced [Ca2]e-dependent contraction was reduced in
female compared with male IVC suggests reduction in the
Ca2 entry mechanisms of venous contraction and reduced
VSM responsiveness to Ca2 entry in female veins. Extra-
cellular Ca2 enters VSM cells through store-operated,
ligand-gated, and voltage-gated Ca2 channels.17,47 Al-
though agonists such as PHE and AngII may activate
various types of Ca2 channels, membrane depolarization
by high KCl mainly activates voltage-gated Ca2 channels.
The observation that the KCl contraction was reduced in
female compared with male IVC, suggests reduced amount
or response to Ca2 entry through voltage-gated Ca2
channels. However, gender-related reduction in Ca2 en-
try through store-operated or ligand-gated Ca2 channels
in female veins cannot be completely ruled out and should
be further examined using electrophysiologic and patch
clamp techniques.
Our results in rat IVC are consistent with reports that
ated relaxation in female rat inferior vena cava (IVC) are
phenylephrine (PHE; 105 M), and the steady-state
or were treated with increasing concentrations (1012 to
C) the ER agonist 4,4,=4==-(4-propyl-[1H]-pyrazole-
is(4-hydroxyphenyl)-propionitrile (DPN), or (E) ICI
eptor 30 stimulant. The effect on PHE contraction was
rs show 5 minutes.medi
with
ated
Rs), (
,3-b
d recthe Ca2 entry mechanisms are reduced in female com-
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consistent with our recent finding of reduced [Ca2]i and
Ca2-dependent constriction in female rat IVC segments
loaded with the Ca2 indicator fura-2.37 The reduced
Ca2 entry could be due to decreased expression/activity
of Ca2 channels in female IVC.
We asked whether the decreased Ca2-dependent
mechanisms of venous contraction in females occur as a
result of increased endothelium-dependent venous relax-
ation pathways. Ach-induced vascular relaxation is often
used to test the endothelium-dependent mechanisms such
as the NO-cyclic guanosine monophosphate (cGMP) vas-
cular relaxation pathway.48,49 The observation that Ach-
induced relaxation was greater in female than male IVC
suggests an enhanced endothelium-dependent venous re-
laxation mechanism in female IVC. The enhanced Ach-
induced relaxation in female IVC could be due to enhanced
release of endothelium-derived factors such as NO. How-
ever, an increased responsiveness of VSM of female rats to
vasodilators cannot be excluded under these conditions.
We tested whether the sex differences in venous con-
traction and endothelium-dependent relaxation are related
to the expression/activity of venous ERs. Most of our
knowledge regarding the amount and function of the vas-
cular ERs are derived from studies on arteries.15,29-32 The
present study demonstrates that ERs are expressed in rat
IVC and that the amounts of ER, ER, and GPR30 are
Fig 6. Estrogen receptor (ER)-mediated venous relaxation was
tested in female rat inferior vena cava (IVC) segments. Segments of
female rat IVC were stimulated with phenylephrine (PHE; 105
M), and the steady-state contraction was recorded. Increasing
concentrations (1012 to 105 M) of 17-estradiol (E2, activator
of most ERs), the ER agonist 4,4,=4==-(4-propyl-[1H]-pyrazole-
1,3,5-triyl)-tris-phenol (PPT), the ER agonist 2,3-bis(4-
hydroxyphenyl)-propionitrile (DPN)or ICI 182,780, the ER/ER
antagonist and G protein-coupled receptor 30 stimulant, were
added and the percentage relaxation of PHE contraction was
measured. Data represent the means	 standard error of the mean
for six vein segments. *Significantly different (P  .05).greater in females than males.These Western blot data in rat veins should be inter-
preted with extreme caution because they are difficult to
extrapolate to human veins. Interestingly, previous immu-
nohistochemical studies in human veins have demonstrated
that ERs were more abundant in tissue sections of varicose
segments than in the nonvaricose parts of the same vein,
especially in women.50 It has also been shown that smooth
muscle cell hypertrophy in varicose veins is associated with
increased expression of ER.51 E2 binds ERs and induces
both genomic and nongenomic effects that promote arte-
rial vasodilation.23-28 The observation that E2 caused sig-
nificant relaxation of female rat IVC suggests that the
venous ER are functional and are involved in venous relax-
ation. E2 binds to all ERs and the venorelxant effects of E2
likely involve activation of most ER subtypes.
The advent of specific agonists to ER subtypes allowed
the examination of the contribution of specific ERs to the
E2 effects. The observation that selective ER and ER
agonists produced significant relaxation in female rat IVC
supports the contention that these ER subtypes contribute
significantly to venous relaxation in the female rat. The
venorelaxant effects of the ER agonist DPN were revers-
ible, supporting specificity of the ER-mediated effects. In
contrast, the vasorelaxant effects of the ER agonist PPT
were not reversible, suggesting that ER activation causes
persistent venous relaxation. However, a potential PPT-
mediated nonspecific blockade of -adrenergic receptors or
direct inhibitory effects on the contractile myofilaments can
not be excluded and should be further examined in future
studies.
GPR30 is a new transmembrane protein that binds E2
and mediates some of its rapid non-genomic effects.33-36
Although ICI 182,780 is largely known as an ER and
ER antagonist, recent studies suggest that it may also
activate GPR30.43,44 The observation that ICI 182,780
caused significant relaxation of female IVC suggests an
important role of GPR30 in E2-mediated venous relax-
ation in females.
E2 has been suggested to promote vasodilation by
activating endothelium-dependent NO-cGMP, PGI2-
cyclic adenosine monophosphate (cAMP), and the EDHF
relaxation pathway.24,25 The observation that the NOS
inhibitor L-NAME did not inhibit the E2-, PPT-, DPN-,
or ICI 182,780-induced relaxation of rat IVC, suggests
that the venous ER may not be coupled to activation of the
NO-cGMP relaxation pathway. The present results can be
explained by the possibility that venous ERs may be cou-
pled to enhanced PGI2-cAMP or EDHF-mediated hyper-
polarization, or both, which in turn cause a reduction in
VSM [Ca2]i and lead to venous relaxation.
52
The present study focused on the effects of E2 and ERs
on venous function. Progesterone is another female sex
hormone that may affect venous function. Previous studies
have demonstrated the expression of progesterone recep-
tors in human saphenous vein, especially in women.50,53
We have also demonstrated rapid inhibitory effects of pro-
gesterone on arterial smooth muscle function.16,46 Study-
ing the effects of progesterone on female veins and its
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 4 Raffetto et al 979potential role in the gender differences in venous function
is an important area for future investigation.
CONCLUSIONS
-Adrenergic, AngII, depolarization-induced, and
[Ca2]e-dependent venous contraction are reduced in fe-
male rat IVC possibly due to increased ER expression/
activity and the enhanced endothelium-dependent but
NO-independent relaxation pathway. The results suggest
inherent sex differences in venous tissues, where the ER-
mediated enhanced venous relaxation and decreased ve-
nous contraction would lead to more distensible veins in
females. One limitation of the present study is that the
experiments were conducted on rat IVC. Future experi-
ments should examine whether the sex differences in ve-
nous function are also present in other rat veins, particularly
those with more relevance to the lower extremity such as
the iliac and femoral veins. We should also note that the rat
is a consistent species, and studies on rat veins avoid the
differences related to age, body weight, ethnic background,
comorbidities, and other confounding factors that are often
encountered in human studies.
The present study on rat veins provided critical mech-
anistic information and suggested sex-related differences in
Fig 7. Effect of nitric oxide synthase (NOS) blockade
tested in female rat inferior vena cava (IVC). Segments o
inhibitor N-nitro-L-arginine methyl ester (L-NAME;
phenylephrine (PHE; 105 M). The steady-state cont
105 M) of (A) 17-estradiol (E2), (B) 4,4,=4==-(4-pr
bis(4-hydroxyphenyl)-propionitrile (DPN), or (D) ICI
contraction was compared in L-NAME-treated and non
error of the mean for five to six vein segments.the mechanisms of venous contraction and relaxation. Per-forming similar venous function experiments to study the
sex differences in human great saphenous vein and in
varicose vs nonvaricose veins would add to our understand-
ing of the mechanisms of venous disease.
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